Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked Article

cited authors

  • Bodor, J. Nicholas; Patel, Jyoti D.; Wakelee, Heather A.; Levy, Benjamin P.; Borghaei, Hossein; Pellini, Bruna; Costello, Michael R.; Dowell, Jonathan E.; Finley, Gene; Huang, Chao H.; Neal, Joel W.; Nieva, Jorge J.; Puri, Sonam; Socinski, Mark A.; Thomas, Christian; Ross, Eric A.; Litwin, Samuel; Clapper, Margie L.; Treat, Joseph

authors

Publication Date

  • November 1, 2023

webpage

published in

category

keywords

  • Anti-VEGF
  • Checkpoint inhibitor
  • Chemotherapy
  • Immunotherapy

start page

  • E242

end page

  • E246

volume

  • 24

issue

  • 7